NICE backs £220,000-a-year Duchenne drug following discountThe National Health Service should fund PTC Therapeutics’ Duchenne Muscular Dystrophy drug, Translarna (ataluren), NICE has said, after Share XNICE backs £220,000-a-year Duchenne drug following discounthttps://pharmaphorum.com/news/nice-backs-ptc-muscular-dystrophy-drug-following-discount/
